8-K: Autolus Therapeutics Receives FDA Approval for AUCATZYL, a Novel CAR T-Cell Therapy for Adult Leukemia

Autolus Therapeutics has secured FDA approval for AUCATZYL, a CAR T-cell therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, marking a significant advancement in treatment options.

Summary

• Autolus Therapeutics has received FDA approval for AUCATZYL (obecabtagene autoleucel) for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
• The approval is based on the FELIX clinical trial, which showed a 63% overall complete remission rate in efficacy-evaluable patients, with 42% achieving complete remission within 3 months.
• The median duration of remission was 14.1 months.
• AUCATZYL is the first CAR T therapy approved by the FDA without a requirement for a REMS program.
• The therapy is designed with a fast target binding off-rate to minimize excessive activation of T cells.
• The company's manufacturing site, The Nucleus, in Stevenage, UK, will supply AUCATZYL globally.
• Cardinal Health will serve as Autolus' commercial distribution partner in the U.S.
• The company plans to engage with existing treatment centers to make AUCATZYL commercially available in the U.S.
• Approximately 8,400 new cases of adult ALL are diagnosed annually in the US and EU, with around 3,000 patients in the relapsed refractory setting.

Sentiment

Score: 8

Explanation: The document is highly positive due to the FDA approval of AUCATZYL, strong clinical trial results, and the potential for commercial success. However, the risks associated with the therapy and the need for successful commercialization temper the overall sentiment slightly.

Positives

• AUCATZYL has demonstrated a high overall complete remission rate of 63% in the FELIX trial.
• The therapy has a median duration of remission of 14.1 months.
• AUCATZYL does not require a REMS program, simplifying its administration.
• The therapy has a novel mechanism of action with a fast off-rate.
• The company has a dedicated manufacturing facility, The Nucleus, ready for commercial production.
• Autolus has a commercial distribution partner in the U.S., Cardinal Health.
• The company has a strong scientific communication and physician engagement within medical affairs.

Negatives

• AUCATZYL carries a boxed warning for Cytokine Release Syndrome (CRS), neurologic toxicities, and secondary hematological malignancies.
• Severe infections, including life-threatening and fatal ones, have occurred in patients after AUCATZYL infusion.
• Grade 3 CRS was reported in 3% of patients, and Grade 3 ICANS in 7% of patients.
• Neurologic toxicities were reported in 64% of patients, including Grade 3 in 12% of patients.
• Prolonged cytopenias, including neutropenia and thrombocytopenia, can occur after treatment.
• Hypogammaglobulinemia and B-cell aplasia can occur after AUCATZYL infusion.
• Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) has occurred after treatment.

Risks

• There are risks associated with Cytokine Release Syndrome (CRS), neurologic toxicities, and secondary hematological malignancies.
• Severe infections are a potential risk following AUCATZYL infusion.
• The therapy may cause prolonged cytopenias, hypogammaglobulinemia, and HLH/MAS.
• There is a risk of hypersensitivity reactions due to DMSO, an excipient used in AUCATZYL.
• The company needs to successfully execute its commercialization strategy.
• Regulatory agencies may affect the progress of clinical trials or future approvals.
• Payors may delay, limit, or deny coverage for AUCATZYL.
• There are risks associated with manufacturing and supply chain logistics.
• The company must maintain intellectual property protection for AUCATZYL.

Future Outlook

Autolus plans to launch AUCATZYL in the U.S., engage with treatment centers, and expand into additional markets. The company is also pursuing regulatory approvals in the EU and UK.

Management Comments

• This milestone approval, based on the demonstrated clinical benefit of AUCATZYL, brings new hope for adult patients with relapsed/refractory B-ALL, said Elias Jabbour, MD.
• Based on the experience in the FELIX trial AUCATZYL is highly active and can be well managed, offering an attractive risk benefit profile for B-ALL patients, said Dr. Claire Roddie, MD, PhD, FRCPath.
• We are so pleased to now be able to offer AUCATZYL, our first commercial product, to adult r/r B-ALL patients in the U.S., said Dr. Christian Itin, Chief Executive Officer of Autolus.
• This milestone is the culmination of many years of hard work, the foundational work by our partners at UCL and the unwavering commitment of our internal team, our external partners and shareholders, said Dr. Christian Itin.

Industry Context

The approval of AUCATZYL represents a significant advancement in the CAR T-cell therapy landscape, particularly for adult patients with r/r B-ALL. It is the first CAR T therapy approved without a REMS program, potentially simplifying its use. The therapy's novel mechanism of action and high remission rates position it as a strong competitor in the market.

Comparison to Industry Standards

• AUCATZYL's 63% overall complete remission rate compares favorably to other CAR T-cell therapies for r/r B-ALL, such as Novartis' Kymriah and Gilead's Tecartus, which have shown remission rates in the 50-80% range in their respective trials.
• The median duration of remission of 14.1 months is also competitive, though some other therapies have shown longer remission durations in certain patient subsets.
• A key differentiator for AUCATZYL is the absence of a REMS program, which is typically required for CAR T-cell therapies due to their potential for severe side effects. This could make AUCATZYL more accessible and easier to administer.
• The fast off-rate mechanism of action is also a unique feature of AUCATZYL, designed to minimize excessive T-cell activation and potentially reduce toxicities.
• The wholesale acquisition cost of $525,000 is within the range of other CAR T-cell therapies, which typically cost several hundred thousand dollars per treatment.

Stakeholder Impact

• Shareholders will likely react positively to the FDA approval and commercialization plans.
• Patients with r/r B-ALL now have a new treatment option with a high remission rate.
• Healthcare providers will need to be trained on the administration and management of AUCATZYL.
• Employees of Autolus will be involved in the manufacturing, distribution, and commercialization of the therapy.
• Suppliers will be involved in the production of AUCATZYL.

Next Steps

• Autolus will engage with existing treatment centers to complete the onboarding process.
• The company will initiate the first scheduling of patients to make AUCATZYL commercially available in the U.S.
• Marketing authorisation applications (MAAs) for obe-cel in adult r/r ALL are being reviewed by the regulators in both the EU and the UK.

Key Dates

Keywords

CAR T-cell therapy, AUCATZYL, obecabtagene autoleucel, B-cell ALL, leukemia, FDA approval, hematological malignancies, immunotherapy, FELIX trial, Cytokine Release Syndrome, Neurotoxicity, REMS, The Nucleus, commercialization